4578.T
Otsuka Holdings Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 12,240.00
+0.41%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2516.4B | 2468.9B | 2329.9B | 2018.6B | 1738.0B |
| Cost of Revenue | 174.1B | 699.1B | 660.4B | 611.2B | 569.5B |
| Gross Profit | 456.3B | 1769.8B | 1669.4B | 1407.3B | 1168.5B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 259.5B | 1004.5B | 958.3B | 807.4B | 724.1B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 771.0M | 3.6B | 3.9B | 6.3B | 6.5B |
| Total Operating Expenses | 260.3B | 1008.1B | 962.2B | 813.6B | 730.6B |
| Cost and Expenses | 2035.2B | 1989.5B | 2006.3B | 1879.0B | 1587.7B |
| Operating Income (EBIT) | 481.2B | 479.4B | 323.6B | 139.6B | 150.3B |
| Non-Operating | |||||
| Interest Income | 6.0B | 15.7B | 21.1B | 9.6B | 28.7B |
| Interest Expense | 2.0B | 27.0B | 8.8B | 6.5B | 6.1B |
| Net Interest Income | 3.9B | (11.3B) | 12.3B | 3.0B | 22.6B |
| Other Non-Op Income/Expense | 4.3B | 63.2B | 23.0B | 5.7B | 23.4B |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 130.2B | 468.0B | 335.9B | 142.7B | 173.0B |
| Income Tax Expense | 30.9B | 101.8B | (11.4B) | 17.2B | 35.5B |
| Bottom Line | |||||
| Net Income | 376.5B | 363.1B | 343.1B | 121.6B | 134.0B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 379.5B | 366.2B | 347.3B | 125.5B | 137.4B |
| Per Share | |||||
| Basic EPS | ¥710 | ¥685 | ¥634 | ¥224 | ¥247 |
| Diluted EPS | ¥710 | — | — | ¥224 | ¥247 |
| Revenue Per Share | ¥4,767 | ¥4,657 | ¥4,303 | ¥3,720 | ¥3,203 |
| Shares | |||||
| Basic Shares Outstanding | 527.9M | 530.1M | 541.4M | 542.7M | 542.6M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | 156.7B | 595.5B | 431.5B | 237.4B | 244.1B |
| D&A | 30.4B | 116.2B | 108.0B | 97.8B | 93.8B |
| EBIT | 481.2B | 479.4B | 323.6B | 139.6B | 150.3B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026